within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AD01_Protionamide;

model Protionamide
  extends Pharmacolibrary.Drugs.ATC.J.J04AD01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J04AD01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Protionamide is a thioamide antibiotic related structurally to ethionamide, used primarily as a second-line agent for the treatment of multidrug-resistant tuberculosis (MDR-TB) and some non-tuberculous mycobacterial infections. It is not widely available in all countries and is not a first-line antituberculous drug.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for an average adult patient based on class similarity to ethionamide (due to lack of direct published data for protionamide). Assumed oral administration in adults.</p><h4>References</h4><ol><li><p>Thee, S, et al., &amp; Schaaf, HS (2016). A review of the use of ethionamide and prothionamide in childhood tuberculosis. <i>Tuberculosis (Edinburgh, Scotland)</i> 97 126–136. DOI:<a href=&quot;https://doi.org/10.1016/j.tube.2015.09.007&quot;>10.1016/j.tube.2015.09.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26586647/&quot;>https://pubmed.ncbi.nlm.nih.gov/26586647</a></p></li><li><p>Venkatesan, K (1989). Clinical pharmacokinetic considerations in the treatment of patients with leprosy. <i>Clinical pharmacokinetics</i> 16(6) 365–386. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198916060-00003&quot;>10.2165/00003088-198916060-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2661102/&quot;>https://pubmed.ncbi.nlm.nih.gov/2661102</a></p></li><li><p>Wu, S, et al., &amp; Fan, G (2020). Validation of a universal and highly sensitive two-dimensional liquid chromatography-tandem mass spectrometry methodology for the quantification of pyrazinamide, ethambutol, protionamide, and clofazimine in different biological matrices. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1151 122141–None. DOI:<a href=&quot;https://doi.org/10.1016/j.jchromb.2020.122141&quot;>10.1016/j.jchromb.2020.122141</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32526663/&quot;>https://pubmed.ncbi.nlm.nih.gov/32526663</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Protionamide;
